Deep Clinical Expertise in Numerous Categories
NAMSA tested nearly 120,000 devices last year so we’ve seen nearly every combination of technologies. We also have extensive preclinical and clinical experience in a wide variety of device categories.
In January 2026, Labcorp divested their Early Development medical device testing business and has entrusted NAMSA to provide these services to their former clients going forward. This includes biocompatibility testing, microbiological testing, analytical chemistry testing and preclinical research. Read the full press release here.
NAMSA helps more medical device manufacturers with biocompatibility testing than any other lab. The benefit to you is access to a very deep pool of medical device testing specialists and toxicologists at our US and European facilities, all of whom are ready to help you develop a plan tailored to your specific device and regulatory pathway.
More than 70% of all global biocompatibility studies are conducted by NAMSA. This matters because we know what testing is required, and our results are trusted by US, EU and other regulators. Instead of engaging multiple labs to perform preclinical, biocompatibility, E&L and microbiology testing, you can save valuable time working with NAMSA.
Medical Device Preclinical Projects Last Year
Board-Certified DaBT Toxicologists on Staff
Fully Equipped ORs and Cath Labs in US and Europe
Medical Device & IVD Focused
From startups to multinationals, NAMSA has been serving the medical device and IVD industries since 1967 and has a highly experienced team ready to serve you. Explore our services.